Retrospective Determination of Prognostic Factors in BRAF- V600E Melanoma Brain Metastases
Lily Erickson, Sahana Ramaswamy, Sherise Ferguson, James Long, Hussein Tawbi, Merve Hasanov, Alicia Bea Davies, Elizabeth Sirmans, Chantal Saberian, Eliza L. Posada, Jared Malke, Lauren Haydu, Caroline Chung
MD ANDERSON CANCER CENTER 3. Atkins MB, Lee SJ, Chmielowski B, et al. DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial — ECOG-ACRIN EA6134. J Clin Oncol . 2021; 39(36): suppl abstr 356154. Conclusions • Highly variable treatment strategies complicate our analysis of treatment response • BRAF-MBM does not follow anticipated patterns from extracranial disease • Initial systemic therapy may improve survival in the context of non-breakthrough MBM Future Directions • Elucidate mechanisms behind treatment-related survival differences • Understand patterns for progression, other outcome metrics Acknowledgements Many thanks to the patients and clinicians that made this study possible. Thank you, also, to the Chung lab for their support. References 1. AlqathamaA. BRAF in malignant melanoma progression and metastasis: potentials and challenges. Am J Cancer Res . 2020; 10(4): 1103-1114. 2. Vellano CP, White MG, Andrews MC, et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature . 2022; 606(7915): 797-803.
Made with FlippingBook - PDF hosting